4,942 Shares in Natera, Inc. (NASDAQ:NTRA) Acquired by Occudo Quantitative Strategies LP

Occudo Quantitative Strategies LP purchased a new stake in Natera, Inc. (NASDAQ:NTRA) during the fourth quarter, Holdings Channel reports. The firm purchased 4,942 shares of the medical research company’s stock, valued at approximately $782,000.

Other large investors have also recently bought and sold shares of the company. Principal Securities Inc. lifted its holdings in Natera by 20.7% during the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock valued at $54,000 after purchasing an additional 59 shares during the last quarter. Gladstone Institutional Advisory LLC increased its holdings in shares of Natera by 1.7% during the fourth quarter. Gladstone Institutional Advisory LLC now owns 3,629 shares of the medical research company’s stock worth $574,000 after buying an additional 61 shares in the last quarter. Silver Oak Securities Incorporated raised its stake in shares of Natera by 3.1% in the fourth quarter. Silver Oak Securities Incorporated now owns 2,963 shares of the medical research company’s stock valued at $470,000 after acquiring an additional 89 shares during the last quarter. Colonial Trust Co SC boosted its holdings in shares of Natera by 7.8% in the 4th quarter. Colonial Trust Co SC now owns 1,325 shares of the medical research company’s stock worth $210,000 after acquiring an additional 96 shares in the last quarter. Finally, Blue Trust Inc. grew its position in Natera by 104.3% during the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock worth $30,000 after acquiring an additional 97 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors.

Natera Stock Down 3.2%

Shares of Natera stock opened at $152.28 on Wednesday. The business has a fifty day simple moving average of $147.91 and a 200 day simple moving average of $156.15. The stock has a market cap of $20.59 billion, a PE ratio of -86.52 and a beta of 1.79. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. Natera, Inc. has a 12 month low of $92.14 and a 12 month high of $183.00.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Thursday, May 8th. The medical research company reported ($0.50) EPS for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.09. The company had revenue of $501.83 million during the quarter, compared to analysts’ expectations of $446.68 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. Natera’s revenue was up 36.5% on a year-over-year basis. During the same period in the prior year, the business posted ($0.56) EPS. Research analysts predict that Natera, Inc. will post -1.49 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. Morgan Stanley increased their target price on Natera from $176.00 to $185.00 and gave the stock an “overweight” rating in a report on Wednesday, March 5th. The Goldman Sachs Group raised their price objective on shares of Natera from $160.00 to $190.00 and gave the company a “buy” rating in a research report on Tuesday, January 28th. StockNews.com upgraded shares of Natera from a “sell” rating to a “hold” rating in a research report on Friday, May 9th. Canaccord Genuity Group reissued a “buy” rating and issued a $180.00 price target on shares of Natera in a report on Wednesday, February 26th. Finally, UBS Group boosted their price objective on shares of Natera from $211.00 to $218.00 and gave the stock a “buy” rating in a research report on Friday, May 9th. One equities research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $181.82.

Insider Activity at Natera

In other Natera news, CEO Steven Leonard Chapman sold 87,272 shares of the stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $143.40, for a total transaction of $12,514,804.80. Following the completion of the transaction, the chief executive officer now owns 203,354 shares in the company, valued at approximately $29,160,963.60. This represents a 30.03% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Gail Boxer Marcus sold 4,000 shares of the business’s stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $151.61, for a total value of $606,440.00. Following the completion of the sale, the director now owns 9,704 shares in the company, valued at approximately $1,471,223.44. This trade represents a 29.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 152,436 shares of company stock worth $22,019,079 in the last quarter. Corporate insiders own 7.60% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.